Monday, April 1, 2019

7 Small-Cap Stocks With Big-Time Potential

There's always a fascination with low-priced small-cap stocks. Maybe it's the "venture capital-like" approach that it brings, or maybe it's the dream of getting in on the ground floor of the next Facebook (Nasdaq: FB) or Amazon (Nasdaq: AMZN).

Whatever the case might be, there's no denying that small-cap stocks can provide investors with astronomical returns. You're more likely to see a small-cap stock with strong growth prospects return triple digits in a year than you are a blue-chip stock.

---Recommended Link---
Wall Street won't tell you about this... but we just uncovered a bombshell...
From custom coded cures to blood cell-sized "nanobots" one company is paving the way towards ending disease as we know it... We've got the company and the ticker that could make you millions.
​Click here for the full details.

That's why I decided it would be fun to fire up my Maximum Profit system and scan the market for small-cap stocks (market cap under $2 billion) with share prices under $10. I also wanted to make sure we weren't getting thinly-traded stocks, or those with low volume, so I made sure that at least 75,000 shares change hands on average daily.

Using a proven system like Maximum Profit to scan for stocks like this is much more efficient than a dart-throwing approach that most investors are likely to take. After all, we're using two proven metrics -- one fundamental, one technical -- to objectively "score" every single stock in the market. By doing this, we've been able to essentially "hack" the market and make gains of 135%, 181%, 242%, and more -- all in a matter of months. 

If we take that approach and narrow it exclusively to small-cap stocks, then we could potentially find some stocks before they go on to deliver some explosive gains...

After I applied the Maximum Profit system to the criteria mentioned above, I found that only eight stocks made it through the screen. One was a current holding in our portfolio already, so I didn't include that one in the final list out of fairness to my existing premium subscribers. That leaves us with these seven:

MP stock screen

Here's a little information on each of the companies in the screen. Three of the seven stocks are gold-related companies, so I'll start there…

1. Eldorado Gold (NYSE: EGO) is a Canadian-based gold mining company with properties in Turkey, Greece, Brazil, Serbia, Canada and Romania. The company's market cap is $964 million, and it generated sales of $459 million in 2018, which was a 17% increase over 2017.

​2. Next up is another Canadian miner, Kinross Gold (NYSE: KGC). This gold and silver miner has properties in the United States, Russia, Brazil, Chile, Ghana, and Mauritania. It has proven and probable reserves of roughly 25.5 million ounces of gold and 53.9 ounces of silver. In 2018 it had sales of just over $3.2 billion, 3% lower than the previous year.

3. The last of the miners is Sibanye Gold (NYSE: SBGL). This company is based in South Africa and operates precious metals mining companies in South Africa, Zimbabwe, and the United States. The company has gold, platinum, palladium, and rhodium operations and projects. It also produces by-products such as iridium, ruthenium, nickel, copper, and chrome. The company is coming off a few strong years of sales growth: from $1.6 billion to over $3.5 billion in the last three years.

4. Akebia Therapeutics (Nasdaq: AKBA) is a biopharmaceutical company that focuses on developing and commercializing novel therapeutics for patients with renal disease. Its lead product candidate is vadadustat, an oral therapy that's in Phase III of the three-stage FDA approval process. Vadadustat is an oral therapy for the treatment of anemia due to chronic kidney disease.

The company is still in its infancy but generated sales of about $208 million in 2018, a 16.7% growth over the prior year. The company hasn't turned a profit yet but does have a solid balance sheet with zero debt and $390 million in cash on hand.

5. Extreme Networks (Nasdaq: EXTR) is a former Maximum Profit holding. We added the communications equipment company to our Small-Cap portfolio in March 2017 and booked a 43.6% gain on the trade in just over four months.

6. Glu Mobile (Nasdaq: GLUU) develops, publishes and markets a portfolio of free-to-play mobile games for smartphones and tablet devices. It primarily publishes titles in four genres, including home décor, sports and action, fashion and celebrity, and time management. Some of its titled games are Contract Killer, Blood & Glory, Cooking Dash, Deer Hunter, QuizUp, and Tap Sports. The company pulled in $366 million in sales in 2018, a 28% increase over the previous year.

7. Zynga (Nasdaq: ZNGA) develops, markets, and operates social games as live services in the United States and internationally. The company's games are played on mobile platforms, as well as social networking sites such as Facebook. For example, one of its more popular games was FarmVille, but it also has Zynga Poker, Words With Friends, CSR Racing 2, and Empires & Puzzles. In 2018, the company generated $861 million in sales, a 16% jump over the previous year.

Action To Take
Keep in mind that the investing ideas I present here are intended to provide a starting point for further research, not a final recommendation. That said, my Maximum Profit subscribers shouldn't be surprised if we see one or more of these stocks in our portfolio at some point.

In the meantime, if you'd like to "hack" the market and earn bigger gains in less time (while avoiding catastrophic losses) in your portfolio like we do over at Maximum Profit, then go here to learn more...

Sunday, March 31, 2019

The Week Ahead: New Technical Warnings?

&l;p&g;&l;img class=&q;dam-image getty size-large wp-image-1074417130&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/1074417130/960x0.jpg?fit=scale&q; data-height=&q;640&q; data-width=&q;960&q;&g; US Federal Reserve Board Chairman Jerome Powell (Photo credit should read JIM WATSON/AFP/Getty Images)

It was another wild FOMC-inspired week in the stock market. Things started off slow, as by Wednesday&a;rsquo;s close, the S&a;amp;P 500 was pretty much unchanged. The comments from Fed Chair Powell about no rate hikes this year did cause some selling late Wednesday, but Wednesday&s;s loss of 0.29% did not erase Monday&a;rsquo;s gain. But chaos reigned on Thursday and Friday. Thursday, the stock market opened strong and the S&a;amp;P 500 closed up 1.09%, but the bullishness did not last long. The S&a;amp;P gapped lower on the open Friday, and closed down 1.90% for the day as it settled just above 2800.

&l;img class=&q;size-full wp-image-20885&q; src=&q;http://blogs-images.forbes.com/tomaspray/files/2019/03/markets.jpg?width=960&q; alt=&q;&q; data-height=&q;213&q; data-width=&q;958&q;&g;

For the week, the small cap Russell 2000 led the market lower, losing just over 3%, followed by a 2.5% decline in the Dow Jones Transportation Average. The Dow Jones Industrial Average was down 1.34%, while the S&a;amp;P 500 was down 0.77%.

All of the market averages are still showing nice YTD gains, with the Nasdaq 100 leading the pack, up 15.8% after it actually closed higher last week. From my perspective, though, the most important consideration is whether there were any changes in the technical outlook.

&l;img class=&q;size-full wp-image-20886&q; src=&q;http://blogs-images.forbes.com/tomaspray/files/2019/03/WA3-22a.jpg?width=960&q; alt=&q;&q; data-height=&q;745&q; data-width=&q;863&q;&g;

Spyder Trust (SPY) has a new high for the year last week at $285.18, but then closed lower at $279.25. The weekly S&a;amp;P 500 &l;a href=&q;http://www.viperreport.com/ad-line-market-timing-stock-picking-trading/&q; target=&q;_blank&q;&g;advance/decline line&l;/a&g; made a new high the week ending March 1&l;sup&g;, &l;/sup&g;but failed to make a new high last week creating a potential bearish or negative divergence.

A drop in the A/D line below the most recent low (point c) will confirm the divergence. It is positive that the Weighted Moving Average of the A/D line is still rising strongly. There is next good support at the former downtrend (line a), which is in the $274 area. The rising 20-week EMA is at $270.91.

&l;img class=&q;size-full wp-image-20887&q; src=&q;http://blogs-images.forbes.com/tomaspray/files/2019/03/WA3-22b.jpg?width=960&q; alt=&q;&q; data-height=&q;745&q; data-width=&q;889&q;&g;

For the past two weeks, the Invesco QQQ Trust (QQQ) has been leading the SPY higher. It made a convincing new high at $182.83 last week but then closed at $178.56. This was 2.3% below the high. The 20-week EMA is rising and now at $169.55.

The weekly Nasdaq 100 A/D line did not make a new high last week, but is not far below the high from March 1. The daily Nasdaq 100 A/D line (not shown) made a new high on Thursday March 21, and did not form any divergences. It is still above its WMA.

&l;img class=&q;size-full wp-image-20888&q; src=&q;http://blogs-images.forbes.com/tomaspray/files/2019/03/WA3-22c.jpg?width=960&q; alt=&q;&q; data-height=&q;792&q; data-width=&q;900&q;&g;

Some of the other A/D lines are also giving a mixed picture. The daily chart of the NYSE Composite shows its close below the 20-day EMA with next strong support at 12,400 (line a). The NYSE All A/D line did make a new high with prices last week, and is still above its rising WMA and support (line b).

The NYSE Stocks Only A/D line peaked on February 22 and has since formed lower highs (indicated by line c). The A/D line closed Friday below its WMA and a drop below the support (line d) would be more negative.

The weekly Russell 2000 A/D line (not shown), which tracks the iShares Russell 2000 (IWM), is declining but is still above its WMA. The daily Russell A/D line (not shown) failed to move above its WMA last week and has now dropped sharply. The weekly and daily Dow Industrial Advance/Decline lines (not shown) are both still positive, and do not show any divergences.

In terms of sentiment, the latest survey of the American Association of Individual Investors revealed that the Bearish-% dropped 7.6 points to 23.4%. This sudden drop in bearish sentiment is consistent with a short-term pullback. But the Bullish-% is at 37.3%, which is close to the long term average and down from the March 1 high at 41.63%. This indicates that there is no sign of serious market weakness based on the sentiment data.

&l;img class=&q;size-full wp-image-20889&q; src=&q;http://blogs-images.forbes.com/tomaspray/files/2019/03/WA3-22d.jpg?width=960&q; alt=&q;&q; data-height=&q;396&q; data-width=&q;900&q;&g;

Even more important to the outlook for the economy and the stock market is the consumer sentiment. The University of Michigan Consumer Sentiment closed in February at 93.8, but the mid-month reading was 97.8 which was a nice improvement. There is major support in the 87.20-88 area (line a). A drop below this level would be negative for stocks and the economy.

The other economic data last week was mixed to slightly positive overall, but the focus Friday was on the brief inversion of the yield curve, as the yield on the 10-Year T-Note fell below the 3-month T-Bill yield.

&l;img class=&q;size-full wp-image-20890&q; src=&q;http://blogs-images.forbes.com/tomaspray/files/2019/03/WA3-22e.jpg?width=960&q; alt=&q;&q; data-height=&q;397&q; data-width=&q;915&q;&g;

According to the &l;a href=&q;https://www.clevelandfed.org/our-research/indicators-and-data/yield-curve-and-gdp-growth.aspx&q; target=&q;_blank&q;&g;Cleveland Federal Reserve&l;/a&g; &a;ldquo;an inverted yield curve (short rates above long rates) indicates a recession in about a year, and yield curve inversions have preceded each of the last seven recessions&a;rdquo;. Their probability chart highlights the past seven recessions, and they allow you to track the probability point by point. From October 2006 through March 2007 the probability rose from 19.1% to 34.3%.

This week, there is a &l;a href=&q;https://us.econoday.com/byweek.asp?day=25&a;amp;month=3&a;amp;year=2019&a;amp;cust=us&a;amp;lid=0&q; target=&q;_blank&q;&g;full economic calendar&l;/a&g;, including reports on Consumer Confidence and GDP, as well as the final monthly rating on the University of Michigan Consumer Sentiment. But for the full schedule, see the calendar. There should be plenty of data to support either a bullish or bearish market outlook by the end of the week.

The formation of the weekly and daily divergences in three of the key advance/decline lines does favor a very cautious strategy for traders. These technical warnings should not be ignored. If these divergences are confirmed by a drop below the early March lows, then a more serious multi-week decline is more likely. The bullish readings from the monthly A/D lines indicates that even longer lasting correction should be a buying opportunity.

Those who followed the four-week dollar-cost averaging plan I recommended &l;a href=&q;https://www.forbes.com/sites/tomaspray/2018/12/23/will-there-be-a-not-going-out-of-business-rally/&q;&g;before Christmas&l;/a&g;, are still 75% long at an average price of 2497 based on the S&a;amp;P 500. On February 25, 25% of the position was sold when the S&a;amp;P 500 moved above 2805.

As a stop on the position, sell the remaining position if the S&a;amp;P 500 has a weekly close below 2597, which is the QPivot.

In my &l;a href=&q;http://guides.viperreport.com/viper-etf/&q; target=&q;_blank&q;&g;Viper ETF Report&l;/a&g; and the &l;a href=&q;http://guides.viperreport.com/viper-hot-stocks/&q; target=&q;_blank&q;&g;Viper Hot Stocks Report&l;/a&g;, I provide my A/D line analysis twice each week with specific buy and sell advice. New subscribers also receive six trading lessons.

&a;nbsp;&l;/p&g;

Sunday, March 24, 2019

Top Medical Stocks To Buy For 2019

tags:GSBD,CDTX,ANSS,GOL,

Most Americans turn to Medicare after their 65th birthdays to give them the assistance they need to cover their healthcare expenses. With estimates of total lifetime medical costs for retired couples soaring toward the $300,000 mark, you can't afford not to make the most of the Medicare benefits to which you're entitled.

Every year, Medicare gives its participants the chance to make key changes to their coverage during the annual open enrollment period. With a start date of Oct. 15, it's smart to take the time now to prepare yourself for the choices you'll have once open enrollment begins. That way, you'll be in the best position possible to use open enrollment to get more value out of your Medicare coverage. Here's some basic information about how Medicare open enrollment works, along with some tips to help you figure out the best way for you to navigate it.

Image source: Getty Images.

Top Medical Stocks To Buy For 2019: Goldman Sachs BDC, Inc.(GSBD)

Advisors' Opinion:
  • [By Shane Hupp]

    Goldman Sachs BDC Inc (NYSE:GSBD) has been given a consensus rating of “Hold” by the eleven analysts that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating, two have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $22.50.

  • [By Motley Fool Transcribers]

    Goldman Sachs BDC, Inc.  (NYSE:GSBD)Q4 2018 Earnings Conference CallMarch 01, 2019, 9:00 a.m. ET

    Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

    Operator

  • [By Max Byerly]

    Stifel Financial Corp trimmed its position in Goldman Sachs BDC Inc (NYSE:GSBD) by 48.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,440 shares of the financial services provider’s stock after selling 11,736 shares during the quarter. Stifel Financial Corp’s holdings in Goldman Sachs BDC were worth $238,000 at the end of the most recent reporting period.

  • [By Ethan Ryder]

    Goldman Sachs BDC (NYSE:GSBD) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $25.00 target price on the stock. According to Zacks, “Goldman Sachs BDC, Inc. is a specialty finance company. The Company invests primarily in telecommunication services, electronic equipment, instruments and components and real estate management and development industries. Goldman Sachs BDC, Inc. is based in NEW YORK, United States. “

Top Medical Stocks To Buy For 2019: Cidara Therapeutics, Inc.(CDTX)

Advisors' Opinion:
  • [By Joseph Griffin]

    These are some of the news headlines that may have impacted Accern’s scoring:

    Get Cidara Therapeutics alerts: Statement re Appointment of Matthew Onaitis as Chief Financial Officer (businesswire.com) Mainstay Medical Announces the Appointment of Matthew Onaitis as Chief Financial Officer (businesswire.com) Cidara finance chief bids adieu (seekingalpha.com) Cidara Therapeutics Inc (CDTX) Receives Average Recommendation of “Buy” from Brokerages (americanbankingnews.com)

    Shares of CDTX stock traded down $0.05 on Wednesday, hitting $4.35. 6,508 shares of the stock traded hands, compared to its average volume of 98,568. The company has a current ratio of 7.11, a quick ratio of 7.11 and a debt-to-equity ratio of 0.12. The firm has a market cap of $120.40 million, a P/E ratio of -1.37 and a beta of 1.99. Cidara Therapeutics has a 1-year low of $3.65 and a 1-year high of $8.80.

  • [By Trey Thoelcke]

    This small-cap biotech company also has big-time potential. Cidara Therapeutics Inc. (NASDAQ: CDTX) is a clinical-stage biotechnology company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.

  • [By Chris Lange]

    Cidara Therapeutics Inc. (NASDAQ: CDTX) shares took a big step back on Monday, despite the firm reporting positive midstage results. Specifically, Cidara reported positive topline results from its Phase 2 Strive clinical trial of its lead antifungal candidate rezafungin acetate.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Cidara Therapeutics (CDTX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top Medical Stocks To Buy For 2019: ANSYS, Inc.(ANSS)

Advisors' Opinion:
  • [By Ethan Ryder]

    ANSYS (NASDAQ: ANSS) and Okta (NASDAQ:OKTA) are both computer and technology companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Ansys (ANSS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Ansys (NASDAQ:ANSS) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “ANSYS delivered strong results for first-quarter 2018, wherein both the top and bottom lines fared better than the respective Zacks Consensus Estimates. Increasing demand for simulation particularly from industries like energy bodes well for ANSYS. We believe that robust product portfolio, expanding total addressable market improving enterprise penetration, collaborations with leading vendors, and strong balance sheet are the catalysts. Acquisitions like 3DSIM and OPTIS are not only enabling ANSYS to bring innovative solutions to the market but are also aiding it to enhance foothold in the competitive simulations market. However, its margin is expected to remain under pressure as ANSYS continues to invest on product development. Furthermore, adverse foreign currency exchange rates are expected to impede revenue growth in the near term as it generates significant revenues from international market.”

Top Medical Stocks To Buy For 2019: Gol Linhas Aereas Inteligentes S.A.(GOL)

Advisors' Opinion:
  • [By Max Byerly]

    Gol Transportes Aéreos (NYSE:GOL) shares traded down 5.4% on Monday . The company traded as low as $9.72 and last traded at $9.75. 524,965 shares traded hands during mid-day trading, an increase of 40% from the average session volume of 374,811 shares. The stock had previously closed at $10.31.

  • [By Logan Wallace]

    Gol Linhas Aereas Inteligentes SA (NYSE:GOL) has received an average rating of “Hold” from the six analysts that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $8.67.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Gol Linhas Aereas Inteligentes (GOL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Wednesday, March 20, 2019

This just might be the worst tax-filing status to claim

If you and your estranged spouse are leading separate lives in separate homes, you might be thinking of filing your taxes that way, too.

Most married couples residing together under the same roof would see fit to file their income taxes on one joint return.

A number of couples have sought the alternative, which is to file under the status of "married filing separately." In this case, each spouse submits their own return and is responsible for their own tax liability.

In the 2016 tax year, the IRS received 3.07 million income tax returns using the "married filing separately" status.

Meanwhile, more than 54 million taxpayers submitted returns as "married filing jointly."

Be aware that just because you can turn in separate tax returns to the IRS doesn't mean that you should.

"Married filing separately isn't the same as just filing as a single taxpayer," said Robert Westley, CPA and member of the American Institute of CPA's personal financial specialist committee.

"Generally it's the least favorable filing status because it limits and can eliminate deductions and credits married couples would otherwise qualify for," he said.

Two situations show chapters Tax collectors chase rich New Yorkers moving to low-tax states    8:53 AM ET Fri, 8 March 2019 | 01:41

Here's one case in which it might make sense to file separately: You have an impending divorce and you've decided you don't trust the accuracy of your spouse's return.

Maybe your estranged spouse's income sources are fishy.

"This is like Carmela Soprano," said Westley, referring to the wife of fictitious TV mob boss Tony Soprano. "You want to file separately and detach your liability from your spouse's return."

Here, giving up the responsibility for the accuracy of your spouse's return trumps any tax savings you'd otherwise get from filing jointly, he said.

Filing separately might also make sense if one spouse has significant unreimbursed medical expenses.

Under the new tax law, filers who itemize on their returns may claim medical expenses only to the extent they exceed 7.5 percent of adjusted gross income for 2018.

"In this case, filing separately will lower their [adjusted gross income] and allow the spouse to achieve a greater deduction," said Westley.

Work with your tax preparer as you determine which status is best for you, because filing separately can come with plenty of disadvantages.

The breaks Jamie Grill | Blend Images | Getty Images

Right out the gates, separate filers wind up with a lower standard deduction.

If you're married and filing separately, you have a standard deduction of $12,000 for 2018, the same as single taxpayers.

Married couples with joint returns are entitled to a $24,000 standard deduction.

Separate filers should also know that if one spouse takes itemized deductions, the other will be required to itemize, as well.

More from Personal Finance
Time is running out to switch Medicare Advantage plans
Taxpayers are leaving $1.4 billion in tax refunds on the table
This professor just had $60,000 in student debt cancelled

This is a key sticking point because the Tax Cuts and Jobs Act has roughly doubled the standard deduction and put limits on itemized deductions.

As a result, people who might have itemized in previous tax years might be better off taking the standard deduction. For couples filing separately, that's not always an option.

"Spouses have to coordinate over whether they will both take the standard deduction or will they both itemize," said Westley.

Lost tax benefits show chapters Protecting your finances during a divorce Protecting your finances during a divorce    4:07 PM ET Tue, 18 Dec 2018 | 01:16

Here are a few tax breaks that may be out of reach for the "married filing separately" crowd.

For instance, the earned income tax credit is likely off the table.

This tax break is for lower income households and can max out $6,444 for households with three or more children for the 2018 tax year.

Couples in which each partner files a separate Form 1040 are also precluded from claiming the student loan interest deduction, which allows you to deduct up to $2,500 in interest paid during the year.

If you're married and you have kids, generally you can only claim the child and dependent care credit if you file a joint return or if you lived apart from your spouse during the last six months of the year.

The child and dependent care credit maxes out at $1,050 for one child under age 13 or $2,100 for two or more kids under 13.

Finally, if you're married and filing separately, you're unable to claim the lifetime learning credit and the American opportunity credit, according to the IRS.

Retirement savings 580502713 Jamie Grill | Getty Images

Filing separate returns can also put a crimp on your retirement accounts.

For instance, joint filers can save up to $6,000 in a Roth individual retirement account in 2019 as long as their modified adjusted gross income is below $193,000. Add $1,000 more if you're over age 50.

However, separate filers who lived with their spouse at any time in the year and who made more than $10,000 in MAGI can't contribute to a Roth IRA.

The restrictions aren't as tough for separate filers who've lived apart from their spouse the whole year. Those people can contribute the maximum $6,000 to the Roth IRA, plus $1,000 if over 50 — as long as their MAGI is below $122,000.

Separate filers may also be unable to fully deduct contributions to their traditional IRA.

"There are a lot of quirks, so it's important to go through and do your tax calculations," said Westley. "One piece can impact another."

Subscribe to CNBC on YouTube.

Sunday, March 17, 2019

How Far Is Dick's Sporting Goods From Its Goals?

In the retail world's ongoing transformation into an omnichannel business, some niche players are adapting. Some, though, are getting lapped. For example, Dick's Sporting Goods (NYSE:DKS), which reported Tuesday on a fourth quarter that featured falling profits, falling comps, falling revenue, and other unfortunate trends. Even after factoring out the 53rd week in fiscal 2017 that made direct comparisons look worse, this was not a winner of a quarter.

In this segment of the MarketFoolery podcast, host Mac Greer and senior analysts Ron Gross and Andy Cross consider the rough results; discuss the few bright spots; reflect on the company's latest modest, but principled, move to sell fewer firearms; weigh the past underperformance of the stock; and speculate about its outlook.

A full transcript follows the video.

This video was recorded on March 12, 2019.

Mac Greer: Let's move on to Dick's Sporting Goods. Shares down Tuesday on earnings. Down big. Ron, falling profits, falling sales, falling same-store sales. That doesn't sound great.

Ron Gross: Not a great quarter, Mac, I think you nailed it! I'll do a little bit of adjusting here because there was a 53rd week in fiscal 2017. So, to be fair, we'll adjust for that. Even when you do, still not a great quarter. Same-store sales down 2.2%. Net sales down 6.5%.

One bright spot, I think we can say, e-commerce sales were up 17%, now accounts for 23% of total sales versus 19% in the fourth quarter of 2017. Making some headway online.

Guidance was somewhat tepid. Interestingly, they did raise their dividend 22%. At that rate, you get a dividend yield of about 3.1%. So, for those looking for a yield, not too shabby. Of course, you always have to be concerned about total return. If you're getting 3% yield but the stock's going down, it's not really something you should be all too excited about. We have to keep an eye on the business. They did buy some stock back over the course of the year at reasonable prices, I think. They've got to turn this ship a bit, though. Not a great quarter.

Greer: Ron, last year after the Parkland shooting, Dick's announced they were going to stop selling firearms to buyers under the age of 21. They also pulled all of their assault-style rifles. Today, they came out and announced that they're going to be removing guns from 125 stores. We don't know which stores, they didn't specify that, but they said in markets where the hunting category underperforms.

Gross: Yeah. They did see some weakness when they did it back after Parkland. I guess that makes sense. The revenue in some markets did go down. I will anticipate that this will have an additional effect, causing revenue to go down, even though they're strategically closing in underperforming markets where that category may have not been so robust. But you'll probably see additional dips. But, you know what? They're making a moral, a political, an ethical, I don't know what word you want to use --

Greer: Principled?

Gross: Principled stance. More power to them. Depending on your politics, you're either happy or you're not. But I applaud them for making a decision. They still have a way to go if they're going to roll this out across the board, because there's more than 700 Dick's Sporting Goods stores and this is only 125. But, baby steps, perhaps.

Greer: Looking out over the last five years, shares down big. They've lost to the market. What do you think about the next five years, Ron?

Gross: The stock looks cheap at 11 times earnings and the 3.1% dividend yield, but I just get worried here. You might make some money in the stock over the long term. I don't think it would be a market-beater, though.

Greer: Andy, when you think of Dick's Sporting Goods, is it Amazon-proof?

Andy Cross: No, it's not. Their inventories grew 67% this past quarter, and with revenues falling, that's a tough sign for retailers. We saw some of the struggles they have with some of the larger brands, especially in the athletic goods over the years. That's going to be a tough spot. I applaud them for the initiatives they're making, but overall, I think Dick's will probably be less relevant over the next five to 10 years than it is today.

Greer: And that's the way the ball bounces.

[crickets chirping]

Guys, that is genius! You didn't like that?

Cross: [laughs] No, I did not like that.

Gross: "Genius" might be a bit of an exaggeration.

Greer: [laughs] I'm kidding!

Thursday, March 14, 2019

American Public Education (APEI) Q4 2018 Earnings Conference Call Transcript

Logo of jester cap with thought bubble with words 'Fool Transcripts' below it

Image source: The Motley Fool.

American Public Education (NASDAQ:APEI) Q4 2018 Earnings Conference CallMarch 12, 2019 5:00 p.m. ET

Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

Operator

Good afternoon. My name is Josh, and I will be your conference operator today. At this time, I would like to welcome everyone to APEI's fourth-quarter and full-year 2018 conference call. [Operator instructions] Thank you.

Chris Symanoskie, vice president of investor relations, please go ahead.

Christopher Symanoskie -- Vice President of Investor Relations

Thank you, operator. Good evening and welcome to American Public Education's discussion of financial and operating results for the fourth-quarter and full-year 2018. Materials that accompany today's conference call are available in the events and presentation section of our website and are included as an exhibit to our current report on Form 8-K furnished with the SEC earlier today. Please note that statements made in this conference call and in the accompanying presentation materials regarding American Public Education or its subsidiaries that are not historical facts may be forward-looking statements based on current expectations, assumptions, estimates and projections about American Public Education and the industry.

These forward-looking statements are subject to risks and uncertainties that could cause actual future events or results to differ materially from such statements. Forward-looking statements can be identified by words such as anticipate, believe, seek, could, estimate, expect, intend, may, should, will and would. These forward-looking statements include, without limitation, statements regarding expected growth; expected registrations and enrollments; expected revenues; expected earnings; and plans with respect to recent, current and future initiatives, investments and partnerships. Actual results could differ materially from those expressed or implied by these forward-looking statements as a result of various factors, including the risk factors described in the risk factors section and elsewhere in the company's most recent annual report on Form 10-K filed with the SEC and the company's other SEC filings.

The company undertakes no obligation to update publicly any forward-looking statements for any reason unless required to by law, even if new information becomes available or other events occur in the future. This evening, it's my pleasure to introduce Dr. Wallace Boston, our president and CEO; and Rick Sunderland, our executive vice president and chief financial officer. Now, I'll turn the call over to Dr.

Boston.

Wally Boston -- President and Chief Executive Officer

Thanks, Chris. Starting with Page 2. I'll begin our call today by discussing APEI's recent operational successes, including robust growth of net course registrations by new students at APUS in the first quarter of 2019. Our CFO, Rick Sunderland, then will discuss APEI's fourth-quarter and full-year financial results as well as our outlook for the first quarter of 2019.

In the fourth quarter of 2018, net course registrations by new students utilizing Military Tuition Assistance or TA increased by 11% compared to the prior year period. Total net course registrations or net course registrations by new students at APUS each declined by approximately 1% year over year. The strong increase in new students utilizing TA was offset by a 4.5% decline in net course registrations by new students utilizing cash and other sources, an 8.3% decrease in course -- net course registrations by new students utilizing veterans benefits or VA as well as an 11.5% decrease in net course registrations by new students utilizing Federal Student Aid or FSA. Our net course registrations by students utilizing FSA declined.

The first course pass and completion rate, a measure of student persistence for APUS undergraduate students utilizing FSA, increased by 8.4% for the three months ended November 30, 2018 compared to the same period last year. Tuition Assistance or TA continues to be the largest pay type category at APUS, representing approximately 48% of new registrations in the fourth quarter of 2018. We believe the strong increase in net course registrations by new students utilizing TA was due in part to extended student advising and admission hours and outreach effectiveness. For the three months ended December 31, 2018 or the fall term of 2018, total enrollment at Hondros College of Nursing or HCN was flat year over year and new student enrollment decreased 4% compared to the prior-year period.

As previously discussed, HCN has implemented multiple changes to its curriculum, course-retake policies and admissions requirements in order to improve the overall first-time NCLEX pass rates for graduates of its ADN program. We believe certain changes had an adverse impact on student enrollment, particularly in the January or winter 2019 term. Beginning with the April or spring 2019 term, HCN has moved an ADN entrance exam requirement used for benchmarking the academic status of the incoming student class to a first-course requirement. As HCN works to identify the appropriate balance of admissions requirements and attracting college-ready students, there may continue to be a negative impact on their enrollments.

We anticipate HCN revenues will be approximately 10% of APEI's consolidated revenues in the first quarter of 2019. In addition to addressing these important matters, the management team at HCN continues to focus on its growth initiatives, including the successful launch of its new Medical Laboratory Technology or MLT program, the implementation of a new branding campaign and preparation for a new campus, which we expect to open in 2020. Because today's earnings call is being conducted after the last ad drop date of the March start, APEI is able to provide actual net course registration results for APUS and HCN, not estimates, in our first-quarter 2019 outlook. I'm very pleased to report that total net course registrations at APUS increased by 1% in the first quarter of 2019 compared to the prior-year period.

The growth was driven by an 8% year-over-year increase in net course registrations by new students. This year-over-year growth in net course registrations is certainly welcome news. The increase in net course registration by new students was largely driven by double-digit year-over-year increase in net course registrations by new active duty military students. We also observed a strengthening of net course registrations by new civilian students despite headwinds from the partial government shutdown in February.

In fact, the year-over-year growth in net course registrations by new students was particularly strong in the months of January and March. This exciting result represents the first year-over-year quarterly increase in net course registrations by new students at APUS since the third quarter of 2012. We believe the improvement in net course registrations at APUS is largely a result of recent upgrades to our enrollment-management processes and improved marketing efficiency as well as a result of offering expanded student services hours. We believe it is also a result of our multiyear effort to stabilize enrollment at APUS through product and process enhancements implemented throughout the entire enterprise.

As we discussed last quarter, our marketing team has been adjusting advertising spend in favor of our most productive channels, with an even greater emphasis on military veteran and other most likely to persist communities. To become more productive, we have utilized new lead scoring methodologies, enhanced geographic recruiting focus and deployed new lead-nurturing strategies to increase engagement and enhance the prospective student's decision process. In addition, we have worked very hard to create a more seamless and personalized onboarding experience for students that we believe has led to improved conversion rates. This, combined with our multiyear effort to create a more engaging classroom experience and attract students with greater academic intent and college readiness, has led to higher student persistence rates, especially among undergraduate students utilizing FSA.

I believe our first-quarter outlook for a year-over-year increase in net course registrations at APUS validates our approach to utilize and leverage our unique core strengths without drastic changes to our business model. As we move forward, we will continue to embrace quality, affordability and flexibility as we serve military veteran and public-service communities with distinction. Now, I will turn the call over to our CFO, Rick Sunderland. Rick?

Rick Sunderland -- Executive Vice President and Chief Financial Officer

Thank you, Wally. Going on to Page 3, financial results. American Public Education's fourth-quarter 2018 consolidated revenue decreased by 1% to $76.9 million, compared to $78.1 million in the prior-year period. The revenue decrease was due to a $1.1 million or 1.6% revenue decrease in our APEI segment and a $0.1 million or 0.8% decrease in revenue in our Hondros segment.

Cost of expenses were $65.5 million for each of the three months ended December 31, 2018 and 2017. Consolidated instructional costs and services expense as a percentage of revenue increased to 37% of revenue, compared to 36.7% in the prior-year period. The increase in instructional costs and services expense as a percent of revenue is primarily driven by increased compensation costs in our Hondros segment, partially offset by a decrease in instructional materials costs in our APEI segment. Selling and promotional expense as a percentage of revenue decreased to 18.2% of revenue, compared to 18.3% in the prior-year period.

The decrease in selling and promotional expense was primarily the result of a decrease in employee compensation costs in our APEI segment, partially offset by an increase in advertising costs in our APEI and Hondros segments. General and administrative expense as a percentage of revenue increased to 24.3% of revenue, compared to 22.3% in the prior-year period. The increase in general and administrative expense is primarily related to increased compensation costs in our APEI and Hondros segments. Consolidated bad debt expense for the quarter was $1.3 million or 1.7% of revenue, compared to $1.1 million or 1.4% of revenue in the prior-year period.

Depreciation and amortization expense as a percentage of revenue decreased to 5.6% of revenue from 5.9% in the prior-year period. Our effective tax rate during the fourth quarter of 2018 was approximately 26.5%, compared to 14.3% in the prior-year period. In the fourth quarter of 2017, we recorded a $3.7 million reduction in income-tax expense related to the revaluation of net deferred tax liabilities resulting from the 2017 Tax Cuts and Jobs Act. Our net income for the quarter was $9.1 million or $0.55 per diluted share, compared to net income of $8.4 million or $0.51 per diluted share in the prior-year period.

Total cash and cash equivalents at December 31, 2018 increased 18.4% to $212.1 million, compared to $179.2 million as of December 31, 2017. For the 12 months ended December 31, 2018, total consolidated revenue was approximately $297.7 million, compared to $299.2 million in the prior-year period. Net income for the 12 months ended December 31, 2018 was $25.6 million or $1.54 per diluted share, compared to net income of $21.1 million or $1.29 per diluted share in the prior-year period. As a reminder, during the full-year 2018, we recorded the following: No.

1, approximately $1.7 million in pre-tax expenses associated with the voluntary reduction in force program announced in March as well as the applicable tax effect of the adjustment. No. 2, approximately $0.7 million pre-tax in professional fees related to an acquisition that the company is no longer pursuing. And No.

3, approximately $1.0 million pre-tax in costs related to the civil investigative demand from the Attorney General of Massachusetts, an inquiry that has since been resolved. Capital expenditures for the year were approximately $9.4 million, compared to $14.8 million in the prior-year period. Decline was primarily related to lower investments in program and software-development costs at APUS. Prior-year program development costs included costs related to doctoral and competency-based education or CBE programs.

Depreciation and amortization for the year was $17.5 million, compared to $18.8 million in the prior-year period. Going on to Page 4, first-quarter 2019 outlook. Our outlook for the first quarter of 2019 is as follows: APUS net course registrations by new students increased approximately 8% year over year. Total net course registrations increased by approximately 1%, compared to the prior-year period.

For the three months ended March 31, 2019, total student enrollment at Hondros declined 15% year over year and new student enrollment decreased by 30% year over year. As Wally noted earlier, enrollments at Hondros were adversely impacted by changes in admissions processes and course-retake policies among other factors. Hondros is taking action which we believe will mitigate the future impact of these changes on enrollment by modifying certain requirements and focusing on growth initiatives. In the first quarter of 2019, we expect a change in consolidated revenue of between 5% decrease and flat year over year.

Net income for the first quarter of 2019 is expected to be in the range of $0.29 to $0.34 per fully diluted share. The change in operating margin indicated by our first-quarter guidance is influenced by seasonality and impacted by two things. No. 1, the guidance includes approximately $1.5 million pre-tax in professional fees associated with an acquisition the company is currently evaluating.

Second and importantly, the enrollment declines at Hondros have a significant impact on that unit's operating margin. We anticipate a year-over-year decline in Hondros segment-operating income of approximately $1.3 million in the first quarter of 2019, compared to the first quarter of 2018. As we mentioned last quarter, APUS continues to adjust its outreach to prospective students by focusing on the military and on the areas of the civilian market, where student quality and advertising costs are more compatible with APUS's low-tuition model. This includes a focus on certain degree programs, professional fields and geographic areas where we've enrolled students that are, on average, more likely to persist.

The results appeared to have been generally favorable, particularly given the double-digit year-over-year increase in net course registrations by new active duty military students, despite the headwinds from the partial government shutdown and the strengthening of net course registrations by new civilian students. In closing, we are pleased by the improved outlook for net course registrations at APUS as well as by the gains we have made with respect to student persistence, particularly among undergraduate students, civilian students utilizing Federal Student Aid. Our team has put forth great effort over many years to improve our enrollment management processes, increase our marketing efficiency and enhance the student learning experience to attract and retain more college-ready students. APEI continues to generate strong free cash flow and it possesses a strong balance sheet with no long-term debt.

Overall, I believe 2018 was a good year for APEI. Now, we'd like to take questions from the audience. Operator, please open the line for questions. 

Questions and Answers:

Operator

[Operator instructions] Your first question comes from Jeff Silber with BMO Capital Markets. Your line is open.

Jeff Silber -- BMO Capital Markets -- Analsyt

Thanks so much. You alluded a couple of times to the government shutdown. I just was wondering if we can get a little bit more detail on the impact you saw. And also, where there any delays in any of the federal funding streams, whether it was Title IV, Department of Defense Tuition Assistance or VA benefits? Thanks.

Wally Boston -- President and Chief Executive Officer

Sure, Jeff. Fortunately, Congress had taken care of DoD, so DoD was funded and all of our main branches of the military had Tuition Assistance funding during the period. VA was also funded, although VA did have some computer problems that weren't related to the shutdown that, we believe, that impacted particularly new VA students, less returning students, but if you were getting your paperwork processed for the first time, it was taking some time. But the Coast Guard is part of the Department of Homeland Security and so the Coast Guard was impacted.

They shut down for the month of February. We didn't get our Coast Guard registrations for that month. And there were some other -- we have some relationships with other agencies like TSA and they were unfunded as well during that time period. So while it wasn't significant, there was an impact on the month of February, but we did have two strong months in both January and March.

Rick Sunderland -- Executive Vice President and Chief Financial Officer

Yeah. This is Rick. I'd like to add to that. So I don't know that we can quantify the impact, but this is where the business model is important.

The shutdown occurred in February with our monthly starts. I believe we were able to recover many of those students, particularly Air Force and -- I'm sorry, Coast Guard and TSA. So for the quarter, we are looking at some pretty significant year-over-year growth in Military Tuition Assistance.

Jeff Silber -- BMO Capital Markets -- Analsyt

OK, that's very helpful. In your discussion on Hondros, I believe you mentioned a new campus essentially opening in 2020. I just was wondering if we can get a little bit more color on that.

Wally Boston -- President and Chief Executive Officer

Yeah, we have approval to open a new campus from a state. I'm not sure if we've given that state out yet. We'll just -- we'll do it when it's the right time. But you may recall, when we had to switch from ACICS as our accrediting body, in last year in June, we got approved by ABHES and they're our new primary accrediting body.

Their rules and regulations say that you have to wait one year to get permission to add a campus. We've already informed ABHES that when our year is up on June 11, we'll submit to them an application to open a new campus. We believe the build-out on that as well as the preparation for signing up students will mean that that campus should open in the spring or roughly the 1st of April for 2020.

Jeff Silber -- BMO Capital Markets -- Analsyt

OK, great. That's very helpful as well. And you gave some color on the expected change year over year for Hondros' operating loss. Can you give us some similar color what you were expecting for APUS in terms of the year-over-year difference on operating income?

Wally Boston -- President and Chief Executive Officer

Well, we're certainly not expecting it to go down, Jeff, but we don't have that quantified. We thought it was helpful in the first quarter, because we know what the change in new student enrollments as well as returning students are to be able to give that for Hondros. But APUS, from a new-student perspective and even overall returning-student perspective, is up in the first quarter.

Rick Sunderland -- Executive Vice President and Chief Financial Officer

If you go back to your modeling historically, I think, you can see the variation across the quarters in terms of margin. Q1 does tend to be a lower-margin quarter, given the start of the tax year.

Jeff Silber -- BMO Capital Markets -- Analsyt

All right. Great. And one more numbers question, if you don't mind. What kind of tax rates you would be using or what's embedded in your guidance for first-quarter EPS? And also, what kind of tax rate would go into the tax effect of transaction costs that you called out, what should we be using as well? Thanks.

Rick Sunderland -- Executive Vice President and Chief Financial Officer

Right. So I might say a good rate going forward is 26.5%. We're going to see a number slightly lower than that in the fourth quarter. We have a small benefit that we're going to take back through expense in that period.

Jeff Silber -- BMO Capital Markets -- Analsyt

But we can view the 26 -- I'm sorry, but we should use that 26.5% also for the transactional costs to kind of tax effect that as well?

Rick Sunderland -- Executive Vice President and Chief Financial Officer

Yes. I would use a slightly lower number than that in the first quarter as we are going to pull in the benefit, small benefit in the first quarter. But that's just the first quarter.

Jeff Silber -- BMO Capital Markets -- Analsyt

OK, great. Got it. I understand. Thank you for clarifying that.

I appreciate it. Thanks.

Rick Sunderland -- Executive Vice President and Chief Financial Officer

Sure.

Operator

Your next question comes from Peter Appert with Piper Jaffray. Your line is open.

Peter Appert -- Piper Jaffray -- Analyst

Thanks. Good afternoon. So Wally, I'm wondering if given the inflection you've seen at APUS here in the current quarter of the changes you have made, if you've got -- your level of confidence basically in terms of the sustainability of positive new course registrations going forward.

Wally Boston -- President and Chief Executive Officer

We feel pretty good. We've made a lot of changes. We've been very patient, particularly in line with trying to make sure we were recruiting quality students in our FSA segment. And it's taken us a lot of time to put processes in place that, Peter, that would make sure that we didn't throw out the baby with the bathwater, but that we were recruiting a student whose interest in college and interest in persisting was much higher than where we were before.

And I think that, along with the fact that we are continuing to emphasize our distinctive ability to meet the needs of our service members and our public-service students is serving us well. And we feel pretty good about it other than later in the year if there's another shutdown, all bets are off. But right now we're feeling pretty good.

Rick Sunderland -- Executive Vice President and Chief Financial Officer

Yeah, I'd like -- so let me add to that. So we've been challenged in returning student numbers, because of the declines in the new-student numbers. So it's really important that we see that growth in the new-student number in the first quarter, because they're only a new student one time and then they become returning students. So if it's a leading indicator, I think, that's a positive, just to see that 8% increase in new students.

Peter Appert -- Piper Jaffray -- Analyst

Sure. How about though the -- just the differential between TA students versus non-TA students, right? The strength is -- if I seem to heard you correctly, the strength is coming primarily from the TA segment. And I'm not sure how to interpret that in terms of -- does that suggest the programmatic offerings are not quite as compelling for the non-TA students? How do you...

Wally Boston -- President and Chief Executive Officer

No, I think one of the things that we talked about last quarter, Peter, was that where we have strengths, we were going to shift our marketing spend to focus on that, so not just in our military programs, but in some of our programs that focus on unique agencies like intel and public, the TSA. At the same time, we talked -- I talked about early on that we've seen some success in geographic focus. So the civilian population in all areas of the country is not the same. And I think, that whether it's a private college or a public college, they'll tell you that.

And so somewhat naively years ago when we got into the -- got approved for FSA, it was advertised equally for all across the board and we found out over time that, quite frankly, in certain areas, people weren't as motivated or as qualified to be college students. And so as we've put processes in, we've also said, you know what, we don't -- we won't advertise in this area, because it meets the profile of the student that we find to be successful and we just won't advertise in this area. We've also been very focused on adding STEM programs and technology programs and have quite a variety. And in the civilian segments that we're recruiting for as well as our military segments, those are proving to be pretty popular.

Peter Appert -- Piper Jaffray -- Analyst

OK, great. Thank you. And then, Wally, the $1.5 million professional fee set, it sounds like a reasonably large number, which might imply a reasonably large transaction. Any color in terms of the kinds of things you're interested in looking at, probability that this goes forward, just anything you could help us with on that?

Wally Boston -- President and Chief Executive Officer

Well, I wish I could give you a high probability. We're certainly hopeful of that, but we've been pretty open about saying that we're looking for healthcare acquisitions. Nursing is our big priority and we'll look at other healthcare options as long as they are going to be able to meet gainful employment requirements, which are still in place, so that's our big focus.

Rick Sunderland -- Executive Vice President and Chief Financial Officer

Yeah. And the other focus would be for non-Title IV and to employment skills gap type companies. So broadly speaking, it's in the area of healthcare and non-Title IV, call it training...

Peter Appert -- Piper Jaffray -- Analyst

But not -- but to be clear, not non-Title IV, exclusively. You're looking at...

Rick Sunderland -- Executive Vice President and Chief Financial Officer

Correct, correct. I mean, the nursing and healthcare would Title IV.

Wally Boston -- President and Chief Executive Officer

Correct.

Peter Appert -- Piper Jaffray -- Analyst

Got it. And presumably, would these be campus-based or are you looking for online assets?

Wally Boston -- President and Chief Executive Officer

Well, online assets would be extremely limited and also an interesting fold-in with APUS, because APUS does have online nursing programs, online-only. So I guess they're out there, but there aren't that many of them, but we continue to want to expand Hondros. I mean, we've said originally when we acquired Hondros that the four original locations, now five, you've got a certain level of overhead and you can run a certain number of facilities with the same number of overhead. So we continue to look for campus expansions and I think we said we'd look to do them organically as well as fold-in acquisitions.

Peter Appert -- Piper Jaffray -- Analyst

Right. Yeah, I would think that given the presence that Hondros gives you, right -- would it not make more sense just to drive expansion through that brand rather than buying another asset?

Wally Boston -- President and Chief Executive Officer

Well, the issue is that with -- it's a creditor. You can only add one location a year, Peter, so that's pretty very slow.

Peter Appert -- Piper Jaffray -- Analyst

OK. OK, got it. All right. Great.

I think I'm covered. Thank you.

Rick Sunderland -- Executive Vice President and Chief Financial Officer

Thank you.

Wally Boston -- President and Chief Executive Officer

Thank you, Peter.

Operator

Your next question comes from Corey Greendale with First Analysis. Your line is open.

Corey Greendale -- First Analysis -- Analyst

Hey. Good afternoon. So first, on the TA side, can you just -- I just kind of lost track of what is permissible and not permissible at this point in terms of marketing tactic. Do you like -- do you have full access to bases at this point? Or is that changing at all?

Wally Boston -- President and Chief Executive Officer

I wish it was changing. We've been working on it since the new administration was in there, but we still have the same MOU from 2014 that only gives guaranteed access to institutions that actually teach on base. So we participate in quarterly office hours or whatever the base's commander has deemed everyone else should participate in, even though there's some bases where we -- our students comprise a substantial majority of all the students using TA. So I think we've done this, Corey, by expanding office hours of our teams, both in advising and student services and admissions, as well as finding ways to, through the process, legitimately to have off-campus events with our outreach people, and that's been effective.

Corey Greendale -- First Analysis -- Analyst

OK. And then, well, you mentioned specifically focusing or not focusing on specific geographic areas, so I had a question around that. There is some talk of changing laws at the state level to try to do some of the things that the prior admiration was going to do at the federal level. So I was just interested if -- I don't know if you've ever kind of given this information -- if there's specific states where you're particularly concentrated or not concentrated.

I'm interested in California and New York since those are two of the higher profile ones that's being discussed. And is that something like that word to be put in place and how would you manage it?

Wally Boston -- President and Chief Executive Officer

Well, we -- before SARA came out, we were licensed in every state that said we had to be licensed there, even though we were online-only. So we've -- I think, we've established good relationships with states, even though many of those states we were able to roll back our licensure, because of SARA. And we are approved for California, even though they're not -- they're the last state that's not a SARA state. So we look at this, Corey, and we hold our record out there that we try to operate above line, in every aspect, try to be transparent.

And so far, it's held us in good stead. And when I talk about some states that we won't advertise in, it's really related to the college preparedness of the students and the income band that we think are attractive at our price point.

Rick Sunderland -- Executive Vice President and Chief Financial Officer

Hey, Corey. It's Rick. So on the military side, the business model is strong in terms of our outreach, the relevance of our programs, our tuition at the TA reimbursement rate. One of the differences is the change in, let's call it, level of service with extended hours in the admissions group and other areas.

So I don't think we can equate a cause and effect, but I think, the overall reengineering of the onboarding process, combined with a redirection of some of our marketing dollars, is producing good results in both the military and the nonmilitary, but you asked about the military.

Corey Greendale -- First Analysis -- Analyst

Yep. Great, that helps. And then on Hondros, it sounds like some of the decline was -- or maybe all of the decline was because of some changes that you made in -- for good motivation, I think, to try to make sure people were prepared. If you -- I just want to make sure I understood that if you shift the timing of that exam to when people already -- to a requirement of the first course, I mean, intuitively what we think will happen is your new student to go up and then your dropout rate will spike, but is that not likely?

Wally Boston -- President and Chief Executive Officer

No. So just talking about that one exam, we are trying to improve our ADN first-time NCLEX pass rates. And so one of the things that we looked at in benchmarking other schools was that, in addition to having a HESI exam, that we require some schools use the ACCUPLACER and believe that's much more indicative of the NCLEX pass rate. And so we put the ACCUPLACER in place for the January term as a required preadmission test and what we found were that some of our prospective students went to other schools that don't have that requirement.

They're just test-averse. And so the idea was not to use the test to weed people out, because I think our benchmark that we're pretty comfortable with is HESI, but just use that test as a benchmark for predicting success and seeing where we could get remedial assistance from an instructional perspective in both Math and English for students. And so with a resistance to take this test before admission, we're building it in and it's not going to be a penalty at all. It's really where are our students when they enter and we can ask them to take that test once they're admitted and then as they go through the program, we can see how they progress.

And ideally, we bring up the first-time NCLEX pass rates, we'll know based on those benchmarks of entering students with the ACCUPLACER as to how far we brought them along.

Corey Greendale -- First Analysis -- Analyst

OK. And last one for me and I'll turn it over. Through this whole period, you've continued to generate good free cash flow. So the first quick one is for Rick.

Just -- can you give us any sense of what capex you'd expect in 2019? And then for either of you, in terms of uses of free cash, I know you're working on acquisitions. Do you think of that as the primary use of cash or what's your capital allocation thinking in 20 -- or free cash capital allocation thinking in 2019?

Rick Sunderland -- Executive Vice President and Chief Financial Officer

Right. So I think the dip we observed in capex in '18 was just that. You'll see capex return to something more along the lines of '17. And in terms of capital allocation, we're seeing opportunities out there.

I mentioned in my portion of the talk about professional fees earlier in '18 related to a potential acquisition as well as fees we're incurring now in the first quarter of '19. So I think, that gives you some sense of our focus here in terms of capital deployment.

Corey Greendale -- First Analysis -- Analyst

All right. Thanks very much.

Operator

[Operator instructions] Your next question comes from Greg Pendy with Sidoti. Your line is open.

Greg Pendy -- Sidoti and Company -- Analyst

Hey, guys. Just, I guess, along those lines as we think about the cash-flow statement, can you just kind of remind us why the receivables spiked in 3Q and that continued in 4Q and when that might normalize, I guess, as we look out to 2019?

Rick Sunderland -- Executive Vice President and Chief Financial Officer

Yeah, the answer is simple, delays in payment in both TA and VA. The largest piece of that is the Air Force. At the end of '17, due to the billing cycle and their payment cycle, literally, there were no months outstanding. And at the end of the third quarter of '18 and repeated at the end of the year '18, there were two months outstanding.

Now, from a collectability standpoint, those are good collectable dollars. The timing of the payment has shifted. So that's the majority of the increase. The remainder, if you really put TA with VA together, you get the vast majority of the increase.

There's just been a slowdown in payments at the Veterans Administration. Again, those are good collectable dollars. They're just being paid more slowly than we have historically experienced. When we talked about that in the third-quarter 10-Q, we talked about the delays, and I think I was purposeful to not say that it was transitory or one-time, because we have no evidence that they're going to return to a prior payment schedule.

Clearly, that would be our goal, but we don't control that. So it's in the -- it's in both the active duty and the veterans.

Greg Pendy -- Sidoti and Company -- Analyst

So it's fair to say you'll hit a payment cycle at least at some point in 2019 to normalize a bit?

Rick Sunderland -- Executive Vice President and Chief Financial Officer

Yes. The point is it will normalize, right? I don't have any expectation that it will get worse and I don't have any expectation that it will get better. And if you have both of those expectations, then it just normalizes.

Greg Pendy -- Sidoti and Company -- Analyst

OK, thanks a lot.

Operator

Your next question comes from Jeff Silber with BMO Capital Markets. Your line is open.

Jeff Silber -- BMO Capital Markets -- Analsyt

Thanks so much. Sorry, just a quick follow-up. I think, you had mentioned that your first-quarter revenue guidance assumes about 10% of that being a contribution from Hondros. That would imply a pretty sizable year-over-year decline.

Obviously, we've seen some pressure on enrollments as well. But from a revenue-per-student perspective, what should we be modeling in for Hondros?

Rick Sunderland -- Executive Vice President and Chief Financial Officer

I don't know that we've ever talked about that.

Wally Boston -- President and Chief Executive Officer

Yeah, that's a great question. Yeah, we don't look at it that way, Jeff, but let's see if we can.

Rick Sunderland -- Executive Vice President and Chief Financial Officer

We'll take that one offline and one of us will follow-up with you.

Jeff Silber -- BMO Capital Markets -- Analsyt

OK, that will be really helpful. Thanks so much. Well, actually let me -- I'm sorry, let's go on. Let me ask the question another way.

The decline you're expecting year over year, I'm assuming that's mostly enrollment-related?

Wally Boston -- President and Chief Executive Officer

At Hondros?

Jeff Silber -- BMO Capital Markets -- Analsyt

Yes.

Wally Boston -- President and Chief Executive Officer

Yeah. And the first-quarter number for new students is going to flow through the rest of the year in returning students, but at the same time, they're hopeful that these changes they made to not quite be as extreme as the first quarter will help them bounce back in subsequent quarters. So they've given us a projection that we're shooting for, for the rest of the year.

Jeff Silber -- BMO Capital Markets -- Analsyt

OK. Thank you so much.

Operator

There are no further questions at this time. I'll turn the call back to Chris Symanoskie.

Christopher Symanoskie -- Vice President of Investor Relations

Great. Thank you. That will conclude our call for today. We wish to thank you for listening and for your interest in American Public Education.

Have a great evening.

Duration: 40 minutes

Call Participants:

Christopher Symanoskie -- Vice President of Investor Relations

Wally Boston -- President and Chief Executive Officer

Rick Sunderland -- Executive Vice President and Chief Financial Officer

Jeff Silber -- BMO Capital Markets -- Analsyt

Peter Appert -- Piper Jaffray -- Analyst

Corey Greendale -- First Analysis -- Analyst

Greg Pendy -- Sidoti and Company -- Analyst

More APEI analysis

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

10 stocks we like better than American Public EducationWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and American Public Education wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of March 1, 2019

Monday, March 11, 2019

Achaogen (AKAO) Stock Price Down 10%

Shares of Achaogen Inc (NASDAQ:AKAO) were down 10% during trading on Friday . The company traded as low as $0.68 and last traded at $0.63. Approximately 6,648 shares changed hands during trading, a decline of 100% from the average daily volume of 1,544,229 shares. The stock had previously closed at $0.70.

A number of analysts recently commented on AKAO shares. Mizuho reiterated a “hold” rating and set a $3.00 price objective on shares of Achaogen in a research report on Friday, February 15th. ValuEngine cut Achaogen from a “hold” rating to a “sell” rating in a research report on Monday, December 17th. HC Wainwright reiterated a “hold” rating and set a $2.00 price objective on shares of Achaogen in a research report on Thursday, February 21st. Wedbush cut Achaogen from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $17.00 to $3.00 in a research report on Monday, November 12th. Finally, SunTrust Banks reiterated a “hold” rating and set a $3.00 price objective (down previously from $10.00) on shares of Achaogen in a research report on Tuesday, November 13th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and one has assigned a buy rating to the stock. Achaogen presently has an average rating of “Hold” and a consensus target price of $8.17.

Get Achaogen alerts:

The company has a debt-to-equity ratio of 1.00, a current ratio of 2.54 and a quick ratio of 2.52. The firm has a market cap of $33.67 million, a P/E ratio of -0.20 and a beta of 1.04.

In other Achaogen news, major shareholder Robert W. Duggan purchased 743,348 shares of the stock in a transaction on Tuesday, December 11th. The stock was bought at an average price of $1.62 per share, for a total transaction of $1,204,223.76. Following the acquisition, the insider now directly owns 8,880,461 shares of the company’s stock, valued at $14,386,346.82. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 8,011 shares of company stock valued at $7,506 in the last 90 days. 7.80% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently bought and sold shares of the business. Rhumbline Advisers grew its holdings in Achaogen by 42.9% in the 4th quarter. Rhumbline Advisers now owns 41,268 shares of the biopharmaceutical company’s stock valued at $51,000 after buying an additional 12,383 shares during the period. Paloma Partners Management Co acquired a new position in shares of Achaogen in the 3rd quarter valued at about $174,000. Bank of Nova Scotia lifted its stake in shares of Achaogen by 900.0% in the 4th quarter. Bank of Nova Scotia now owns 50,000 shares of the biopharmaceutical company’s stock valued at $62,000 after purchasing an additional 45,000 shares in the last quarter. First Midwest Bank Trust Division acquired a new position in shares of Achaogen in the 4th quarter valued at about $69,000. Finally, Jefferies Group LLC acquired a new position in shares of Achaogen in the 3rd quarter valued at about $275,000. Institutional investors own 43.27% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Achaogen (AKAO) Stock Price Down 10%” was originally posted by Ticker Report and is owned by of Ticker Report. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.tickerreport.com/banking-finance/4210896/achaogen-akao-stock-price-down-10.html.

About Achaogen (NASDAQ:AKAO)

Achaogen, Inc, a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.

Featured Story: When is a capital gain realized?

Saturday, March 9, 2019

Dollar Tree says it will test charging more

Dollar Tree is shaking things up.

The discount retailer says that it will shutter as many as 390 Family Dollar stores this year, change the name of roughly 200 more, and will start testing charging more than a dollar in some of its namesake stores.

The string of announcements came as Dollar Tree reported its fourth-quarter earnings.

The Chesapeake, Virginia-based Dollar Tree bought its rival Family Dollar for $9.2 billion in 2015. but the brand has been ailing. The final number of Family Dollar stores that will close depends on its parent company's ability to get rent concessions from landlords, Dollar Tree said. It already closed 84 underperforming Family Dollar stores in the fourth quarter, which was 37 more than it had planned to shutter last year.

Dollar Tree reported nearly in-line quarterly results before the markets opened on Wednesday but disappointing earnings guidance. Yet shares were up early on. (Photo: https://www.flickr.com/photos/jeepersmedia/)

It will also stamp its name on roughly 200 Family Dollar stores.

But Family Dollar is not the only company brand going through changes.

Kylie Jenner? Really?: Kylie Jenner? Self-made billionaire? Twitter's aflutter about makeup mogul's new status

Ferrari V8 gets the spotlight: Most powerful Ferrari V8 ever to debut at Geneva auto show

How to make the most of interest rates: How to take advantage of rising interest rates by finding the best savings account

Dollar Tree CEO Gary Philbin also mentioned plans to test selling items that cost more than a buck at its namesake chain, a shift that's reportedly been pushed by an activist investor.

Dollar Tree has tested the pricing change before, but Philbin shared no details about the locations where the new test will be done, what the new prices specifically will be, or how many items, or product categories, would be included.

It's a marked change for the brand, which has traditionally used $1 as its cut-off price point, while Family Dollar sold not only $1 items but products that cost more.

John Zolidis, president of Quo Vadis Capital, said that because of its Family Dollar acquisition, Dollar Tree believes it now has the expertise to try to boost prices at its namesake stores. But it's a risky proposition.

"The $1-only proposition is what makes people love Dollar Tree so much," Zolidis said. "Moving away from that brand equity does present a pretty significant risk to the concept on a long-term basis if it becomes just another store. Right now, it's unique."

But in the short-term, testing higher prices could be helpful, he added. Doing so would raise the company's profit margins, as it faces pressures ranging from rising labor costs to tariffs, and possibly make up for the unexpectedly sluggish performance of the Family Dollar brand.

NEWSLETTERSGet the Managing Your Money newsletter delivered to your inboxWe're sorry, but something went wrongA collection of articles to help you manage your finances like a pro.Please try again soon, or contact Customer Service at 1-800-872-0001.Delivery: FriInvalid email addressThank you! You're almost signed up for Managing Your MoneyKeep an eye out for an email to confirm your newsletter registration.More newsletters

Neil Saunders, managing director of retail consultancy GlobalData, also said that a different pricing structure "is a sensible move that will give the company significant flexibility in dealing with cost increases.''

While some shoppers might initially be turned off "longer term, we see no real reason why this move can't work, especially given it is employed by Dollar General and a number of other value players.''

The chain is also trying to boost profits by closing stores, a move that could also create leverage when negotiating with its landlords, Zolidis said.

Dollar Tree still plans to invest in its Family Dollar brand, however, renovating at least 1,000 stores this year. The cost to remodel a store ranges from $100,000 to $150,000, CFO Kevin Wampler said.

 

Follow USA TODAY reporters Zlati Meyer on Twitter: @ZlatiMeyer and Charisse Jones @charissejones

Friday, March 8, 2019

$0.02 EPS Expected for Nordic American Tanker Ltd (NAT) This Quarter

Equities research analysts expect Nordic American Tanker Ltd (NYSE:NAT) to announce earnings of $0.02 per share for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Nordic American Tanker’s earnings. The highest EPS estimate is $0.13 and the lowest is ($0.10). Nordic American Tanker reported earnings of ($0.13) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 115.4%. The business is expected to announce its next quarterly earnings report on Wednesday, May 15th.

Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that cover Nordic American Tanker.

Get Nordic American Tanker alerts:

Nordic American Tanker (NYSE:NAT) last issued its quarterly earnings data on Tuesday, February 19th. The shipping company reported ($0.05) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.01) by ($0.04). The company had revenue of $44.19 million during the quarter, compared to analyst estimates of $48.97 million. Nordic American Tanker had a negative net margin of 76.09% and a negative return on equity of 10.80%.

NAT has been the subject of several analyst reports. Zacks Investment Research raised Nordic American Tanker from a “hold” rating to a “buy” rating and set a $2.25 price objective for the company in a report on Friday, January 4th. ValuEngine raised Nordic American Tanker from a “sell” rating to a “hold” rating in a report on Monday, January 7th. Seaport Global Securities set a $3.00 price objective on Nordic American Tanker and gave the company a “hold” rating in a report on Monday, November 12th. Maxim Group set a $1.00 price objective on Nordic American Tanker and gave the company a “sell” rating in a report on Wednesday, February 20th. Finally, B. Riley initiated coverage on Nordic American Tanker in a report on Friday, November 9th. They issued a “buy” rating and a $4.25 price objective for the company. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. Nordic American Tanker presently has a consensus rating of “Hold” and an average price target of $2.60.

Shares of NAT stock traded down $0.07 on Friday, hitting $2.04. The company had a trading volume of 1,460,156 shares, compared to its average volume of 1,344,646. The stock has a market cap of $299.56 million, a PE ratio of -3.34 and a beta of 0.51. The company has a quick ratio of 3.50, a current ratio of 4.29 and a debt-to-equity ratio of 0.67. Nordic American Tanker has a twelve month low of $1.81 and a twelve month high of $3.47.

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 15th. Investors of record on Friday, March 1st will be issued a $0.04 dividend. The ex-dividend date is Thursday, February 28th. This represents a $0.16 dividend on an annualized basis and a yield of 7.84%. Nordic American Tanker’s payout ratio is -6.56%.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC acquired a new position in Nordic American Tanker in the 2nd quarter worth about $142,000. Raymond James & Associates raised its holdings in Nordic American Tanker by 89.3% in the 2nd quarter. Raymond James & Associates now owns 52,165 shares of the shipping company’s stock worth $140,000 after purchasing an additional 24,603 shares during the period. Greylin Investment Mangement Inc. raised its holdings in Nordic American Tanker by 6.9% in the 4th quarter. Greylin Investment Mangement Inc. now owns 1,839,920 shares of the shipping company’s stock worth $3,680,000 after purchasing an additional 118,975 shares during the period. BlackRock Inc. raised its holdings in Nordic American Tanker by 1.6% in the 3rd quarter. BlackRock Inc. now owns 7,232,489 shares of the shipping company’s stock worth $15,116,000 after purchasing an additional 112,110 shares during the period. Finally, WealthTrust Axiom LLC raised its holdings in Nordic American Tanker by 3.8% in the 4th quarter. WealthTrust Axiom LLC now owns 986,176 shares of the shipping company’s stock worth $1,972,000 after purchasing an additional 35,858 shares during the period. 25.02% of the stock is owned by institutional investors.

About Nordic American Tanker

Nordic American Tankers Limited, a tanker company, acquires and charters double-hull tankers in Bermuda and internationally. It operates a fleet of 33 Suezmax crude oil tankers. The company was founded in 1995 and is based in Hamilton, Bermuda.

Recommended Story: What type of investment options does a Roth IRA provide?

Get a free copy of the Zacks research report on Nordic American Tanker (NAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nordic American Tanker (NYSE:NAT)

Thursday, March 7, 2019

Here's Why CareDX Is on the Move Today

What happened

Shares of CareDx (NASDAQ:CDNA), a specialized diagnostics company, jumped 16% during morning trading in response to the company's fourth-quarter earnings report. Investors pleased to see continued profitability have driven the stock 9.7% higher as of 3:29 p.m. EST on Thursday.

So what 

For a decade now, CareDx's AlloMap test has been helping heart transplant patients know how many immunosuppressants they should be taking with a blood test instead of a biopsy. AlloMap's popularity during the fourth quarter rose 6% compared to a year earlier, to 4,057 tests recorded.

Guy in a suit with a jetpack taking off.

Image source: Getty Images.

CareDx investors are excited because the company's more recently launched kidney rejection test, AlloSure, has already outpaced AlloMap. In the fourth quarter, 4,575 kidney transplant recipients had their blood checked for early signs of rejection with AlloSure, avoiding biopsies in the process.

CareDx already told investors about AlloSure's surge when it reported preliminary results in January. The stock jumped today because adjusted EBITDA climbed from $0.2 million in the third quarter to $0.8 million during the fourth.

Now what

CareDx expects total revenue to rise from $76.6 million last year to between $105 million and $107 million in 2019. The company didn't provide bottom-line guidance, but the chances of this company posting another significant loss in 2018 look awfully slim. In 2018, the company narrowed its net loss for the entire year to $46.8 million and extinguished all of its debt.

AlloSure's the first noninvasive test for early signs of kidney rejection, and it's only penetrated 3% of its patient population so far. At recent prices, CareDx is trading at 13.2 times forward sales, which isn't bad for a company that just reported total annual revenue 58% higher than a year earlier.

If AlloSure continues to exceed expectations, CareDx shareholders can look forward to some market-thumping gains in the years ahead.

Sierra Oncology Inc to Post Q1 2019 Earnings of ($0.21) Per Share, Jefferies Financial Group Forecas

Sierra Oncology Inc (NASDAQ:SRRA) – Equities research analysts at Jefferies Financial Group issued their Q1 2019 earnings estimates for Sierra Oncology in a research report issued on Monday, March 4th. Jefferies Financial Group analyst M. Raycroft forecasts that the biotechnology company will post earnings of ($0.21) per share for the quarter. Jefferies Financial Group also issued estimates for Sierra Oncology’s FY2023 earnings at $0.13 EPS.

Get Sierra Oncology alerts:

Separately, Wedbush reaffirmed an “outperform” rating on shares of Sierra Oncology in a report on Thursday, February 28th.

Shares of SRRA opened at $1.83 on Wednesday. Sierra Oncology has a 12-month low of $1.05 and a 12-month high of $3.70. The company has a quick ratio of 14.68, a current ratio of 14.68 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $146.51 million, a price-to-earnings ratio of -2.44 and a beta of 1.61.

Sierra Oncology (NASDAQ:SRRA) last issued its earnings results on Thursday, February 28th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.01.

In other news, Director Andrew R. Allen bought 66,000 shares of the stock in a transaction on Monday, December 10th. The stock was acquired at an average price of $1.64 per share, with a total value of $108,240.00. Following the acquisition, the director now directly owns 66,000 shares in the company, valued at $108,240. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 5.61% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Acadian Asset Management LLC grew its position in shares of Sierra Oncology by 5.4% in the 4th quarter. Acadian Asset Management LLC now owns 407,105 shares of the biotechnology company’s stock valued at $538,000 after buying an additional 20,754 shares during the last quarter. Bridgeway Capital Management Inc. grew its position in shares of Sierra Oncology by 36.9% in the 3rd quarter. Bridgeway Capital Management Inc. now owns 225,000 shares of the biotechnology company’s stock valued at $383,000 after buying an additional 60,700 shares during the last quarter. Morgan Stanley grew its position in shares of Sierra Oncology by 11.3% in the 3rd quarter. Morgan Stanley now owns 992,516 shares of the biotechnology company’s stock valued at $1,687,000 after buying an additional 100,709 shares during the last quarter. Hikari Power Ltd bought a new stake in shares of Sierra Oncology in the 4th quarter valued at about $330,000. Finally, Algert Global LLC grew its position in shares of Sierra Oncology by 173.8% in the 3rd quarter. Algert Global LLC now owns 394,258 shares of the biotechnology company’s stock valued at $670,000 after buying an additional 250,267 shares during the last quarter. Hedge funds and other institutional investors own 60.61% of the company’s stock.

About Sierra Oncology

Sierra Oncology, Inc, a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer.

Featured Article: Google Finance Portfolio Tips and Tricks

Earnings History and Estimates for Sierra Oncology (NASDAQ:SRRA)